Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium-histidine-acetyl-neurotensin (8-13) is a synthetic peptide analogue derived from the C-terminal hexapeptide fragment of neurotensin, a 13-amino acid neuropeptide. This peptide is designed to target and bind to neurotensin receptors, particularly neurotensin receptor 1 (NTS1R), which are often overexpressed in various malignant tumors, including small-cell lung cancer, pancreatic carcinoma, colon carcinoma, breast cancer, and prostate cancer. The histidine-acetyl modification facilitates its labeling with radionuclides, such as 99mTechnetium (99mTc), to create radiopharmaceuticals for diagnostic imaging. Its primary application is in radionuclide imaging to visualize neurotensin receptor-positive tumors, leveraging its specific binding and subsequent internalization by cancer cells. The peptide's stability and high affinity for NTS1R make it a promising candidate for targeted cancer diagnostics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium-histidine-acetyl-neurotensin (8-13).